Liminatus Pharma, Inc. Class A Common Stock (LIMN) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 518 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -518 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 1.1M | 884.21K | 701.17K | 1.12M | 255 | 522.79K | 1.02M | 642.08K | 1.71M | 642.7K | 676.32K |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 700.9K | 884.21K | 701.17K | 1.12M | 0 | 167K | 186.08K | 195.08K | 96K | 47K | 676.32K |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 400K | 0 | 0 | 0 | 0 | -200 | 357.07K | 714.13K | 1.61M | 715K | 0 |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 255 | 355.99K | 476.55K | -267.14K | 0 | -119.3K | 0 |
| Operating Income | -1.1M | -884.21K | -701.17K | -1.12M | -255 | -522.79K | -1.02M | -642.08K | -1.71M | -642.7K | -676.32K |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -431624.71% | -69.13% | 31.24% | -74.15% | 99.99% | 18.66% | -50.77% | - | - | - | - |
| EBITDA | -1.1M | -883.67K | -700.63K | -1.12M | -255 | -728.5K | -637.74K | -530.07K | -1.69M | -369.91K | -300.29K |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -431624.71% | -21.3% | -9.86% | -110.81% | 99.98% | -96.94% | -112.37% | - | - | - | - |
| D&A (Non-Cash Add-back) | 0 | 543 | 542 | 743 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | -1.1M | -8.15M | -1.8M | 175.57K | -255 | -728.5K | -637.74K | -530.07K | -1.69M | -369.91K | -300.29K |
| Net Interest Income | -18.64K | -19.05K | -19.05K | -37.91K | -115.51K | -112.64K | -58.23K | -51.99K | -44K | -9K | 421.85K |
| Interest Income | 0 | 0 | 0 | 24.38K | 0 | 24.13K | 34.48K | 25.23K | 19K | 8K | 421.85K |
| Interest Expense | 18.64K | 19.05K | 19.05K | 62.29K | 115.51K | 136.76K | 92.71K | 77.22K | 63K | 17K | 0 |
| Other Income/Expense | -22.82K | -7.28M | -1.12M | 1.23M | 0 | -342.47K | 381.96K | 112.01K | -44K | 169.7K | 376.03K |
| Pretax Income | -1.12M | -8.17M | -1.82M | 113.29K | -255 | -865.26K | -637.74K | -530.07K | -1.75M | -473K | -300.29K |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 3.05K | 5.16K | 4.78K | 0 | 13.6K | 23.6K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | -0.35% | -0.81% | -0.9% | 0% | -2.88% | -7.86% |
| Net Income | -1.12M | -8.17M | -1.82M | 113.29K | -255 | -868.31K | -642.9K | -534.85K | -1.75M | -486.6K | -323.89K |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -440572.16% | -840.78% | -183.61% | 121.18% | 99.99% | -78.45% | -98.49% | - | - | - | - |
| Net Income (Continuing) | -1.12M | -8.17M | -1.82M | 113.29K | -255 | -868.31K | -642.9K | -534.85K | -1.75M | -486.6K | -323.89K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.05 | -0.30 | -0.07 | 0.00 | -2.55 | -0.12 | -0.09 | -0.07 | -0.23 | -0.07 | -0.04 |
| EPS Growth % | 98.15% | -150% | 24.67% | 106.59% | -1008.7% | -80.18% | -125.13% | - | - | - | - |
| EPS (Basic) | -0.05 | -0.30 | -0.07 | 0.00 | -2.55 | -0.12 | -0.09 | -0.07 | -0.23 | -0.07 | -0.04 |
| Diluted Shares Outstanding | 23.75M | 23.75M | 27.01M | 23.3M | 27.06M | 7.07M | 7.17M | 7.19M | 7.6M | 7.31M | 8.13M |
| Basic Shares Outstanding | 23.75M | 23.75M | 27.01M | 23.3M | 27.06M | 7.07M | 7.17M | 7.19M | 7.6M | 7.31M | 8.13M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - |